Status:
COMPLETED
Use of Continuous Glucose Monitors in Coronavirus Disease 2019 ICU and Potential Inpatient Settings
Lead Sponsor:
University Hospitals Cleveland Medical Center
Conditions:
Covid19
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of the study is to improve glycemic control in inpatient/ICU settings using real- time continuous glucose monitors (CGM) data for insulin titration. It may help reduce Coronavirus diseas...
Detailed Description
Due to the increasing need for acute care of COVID-19 patients in ICU settings, the use of continuous glucose monitors (CGM) as a means to reduce patient contact and remotely improve glycemic control ...
Eligibility Criteria
Inclusion
- Coronavirus disease 2019 tested positive patient
- Age over 18 years
- Admitted to Coronavirus disease 2019 specific ICU, with possible transfer to inpatient unit when stable
- Patients with known or acquired Type 1 or Type 2 Diabetes requiring insulin therapy during admission
Exclusion
- In state of active diabetic ketoacidosis (DKA) at time of enrollment
- Two or more vasopressors in use at time of sensor placement
- Unable to use at predetermined sensor site based on assessment of skin health
Key Trial Info
Start Date :
June 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05343624
Start Date
June 18 2020
End Date
December 1 2021
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical center
Cleveland, Ohio, United States, 44106